Benlysta Solution
NDC Package 49401-088-47
Package Information
Benlysta (belimumab) solution is bENLYSTA is indicated for the treatment of patients 5 years of age and older with:•Active systemic lupus erythematosus (SLE) who are receiving standard therapy, and•Active lupus nephritis who are receiving standard therapy.Limitations of UseThe efficacy of BENLYSTA has not been evaluated in patients with severe active central nervous system (CNS) lupus. This formulation utilizes a solution delivery system. Marketed by Glaxosmithkline Llc, this product is identified by NDC 49401-088 and is authorized under FDA application BLA761043.
Identification & Billing
- RxCUI: 1656395 - belimumab 120 MG Injection
- RxCUI: 1656398 - Benlysta 120 MG Injection
- RxCUI: 1656398 - belimumab 120 MG Injection [Benlysta]
- RxCUI: 1656400 - belimumab 400 MG Injection
- RxCUI: 1656402 - Benlysta 400 MG Injection
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 49401 - Glaxosmithkline Llc
- 49401-088 - Benlysta
- 49401-088-47 - 4 SYRINGE in 1 CARTON / 1 mL in 1 SYRINGE (49401-088-42)
- 49401-088 - Benlysta
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (49401-088). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 49401-088-47 identifies a specific commercial package of 4 syringe in 1 carton / 1 ml in 1 syringe (49401-088-42) of Benlysta, a human prescription drug labeled by Glaxosmithkline Llc. This product is billed per "ML" milliliter and contains an estimated amount of 4 billable units per package. This solution is formulated for subcutaneous use and contains belimumab as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Glaxosmithkline Llc on July 20, 2017. The current certification is valid through December 31, 2027.
How is this Glaxosmithkline Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 49401008847. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 4 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.